Advertisement

Drugs

, Volume 63, Issue 6, pp 525–534 | Cite as

Nonsteroidal Anti-Inflammatory Drugs and Heart Failure

  • Gysèle S. Bleumink
  • Johannes Feenstra
  • Miriam C. J. M. Sturkenboom
  • Bruno H. Ch. Stricker
Current Opinion

Abstract

Heart failure constitutes an increasing public health problem because of the growing incidence and prevalence, poor prognosis and high hospital (re)admission rates. Myocardial infarction is the underlying cause in the majority of patients, followed by hypertension, valvular heart disease and idiopathic cardio-myopathy.

Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the enzymes cyclo-oxygenase (COX) 1 and 2, have been associated with the occurrence of symptoms of heart failure in several case reports and quantitative studies, mainly in patients with a history of cardiovascular disease or left ventricular impairment. NSAIDs may impair renal function in patients with a decreased effective circulating volume by inhibiting prostaglandin synthesis. Consequently, water and sodium retention, and decreases in renal blood flow and glomerular filtration rate may occur, affecting the unstable cardiovascular homeostasis in these patients. In patients with pre-existing heart failure, this may lead to cardiac decompensation. Putative renal-sparing NSAIDs, such as COX-2 selective inhibitors have similar effects on renal function as the traditional NSAIDs, and can likewise be expected to increase the risk of heart failure in susceptible patients. NSAIDs are frequently prescribed to elderly patients, who are particularly at risk for the renal adverse effects. If treatment with NSAIDs in high risk patients cannot be avoided, intensive monitoring and patient education is important.

Keywords

Heart Failure Celecoxib Naproxen Rofecoxib Renal Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000 May; 83(5): 596–602PubMedCrossRefGoogle Scholar
  2. 2.
    Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991 Mar; 121 (3 Pt 1): 951–7PubMedCrossRefGoogle Scholar
  3. 3.
    Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993 Oct; 22 (4 Suppl A): 6A–13APubMedCrossRefGoogle Scholar
  4. 4.
    Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001 Aug; 22(15): 1318–27PubMedCrossRefGoogle Scholar
  5. 5.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure) J Am Coll Cardiol 2001 Dec; 38(7): 2101–13PubMedCrossRefGoogle Scholar
  6. 6.
    Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001 Sep; 22(17): 1527–60PubMedCrossRefGoogle Scholar
  7. 7.
    Packer M. Pathophysiology of chronic heart failure. Lancet 1992 Jul 11; 340(8811): 88–92PubMedCrossRefGoogle Scholar
  8. 8.
    Feenstra J, Grobbee DE, Remme WJ, et al. Drug-induced heart failure. J Am Coll Cardiol 1999 Apr; 33(5): 1152–62PubMedCrossRefGoogle Scholar
  9. 9.
    Tashima CK, Rose M. Pulmonary edema and salicylates [letter]. Ann Intern Med 1974 Aug; 81(2): 274–5PubMedGoogle Scholar
  10. 10.
    Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977 Apr 18; 237(16): 1716–7PubMedCrossRefGoogle Scholar
  11. 11.
    Nevins M, Berque S, Corwin N, et al. Phenylbutazone and pulmonary oedema. Lancet 1969 Dec 20; 2(7634): 1358PubMedCrossRefGoogle Scholar
  12. 12.
    Van den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing 1988 Jan; 17(1): 8–16PubMedCrossRefGoogle Scholar
  13. 13.
    Feenstra J, Stricker BHC. Heart failure and fluid retention attributed to the use of non-steroidal anti-inflammatory drugs [in Dutch]. Ned Tijdschr Geneeskd 1996 Oct 5; 140(40): 2000–3PubMedGoogle Scholar
  14. 14.
    Brooks P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med 1998 Mar 30; 104(3A): 9S–13SPubMedCrossRefGoogle Scholar
  15. 15.
    Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997 Sep 15; 127(6): 429–38PubMedGoogle Scholar
  16. 16.
    Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001 Jan–Feb; 21(1): 1–15PubMedCrossRefGoogle Scholar
  17. 17.
    Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996 Jul; 28 (1 Suppl. 1): S56–62PubMedCrossRefGoogle Scholar
  18. 18.
    Feenstra J, Grobbee DE, Mosterd A, et al. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf 1997 Sep; 17(3): 166–80PubMedCrossRefGoogle Scholar
  19. 19.
    Hirsch AT, Dzau VJ, Creager A. Broreceptor function in congestive heart failure: effect on neurohormonal activation and regional vascular resistance. Circulation 1987 May; 75 (5 Pt 2): IV36–48PubMedGoogle Scholar
  20. 20.
    Baughman KL. B-type natriuretic peptide-a window to the heart. N Engl J Med 2002 Jul 18; 347(3): 158–9PubMedCrossRefGoogle Scholar
  21. 21.
    Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation 1988 Jun; 77 (6 Pt 2): 164–73CrossRefGoogle Scholar
  22. 22.
    Davies NM, Skjodt NM. Choosing the right nonsteroidal anti-inflammatory drug for the right patient. Clin Pharmacokinet 2000 May; 38(5): 377–92PubMedCrossRefGoogle Scholar
  23. 23.
    Simon LS, Mills JA. Drug therapy: nonsteroidal antiinflam-matory drugs (first of two parts). N Engl J Med 1980 May 22; 302(21): 1179–85PubMedCrossRefGoogle Scholar
  24. 24.
    Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993 Mar 25; 268(9): 6610–4PubMedGoogle Scholar
  25. 25.
    Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993 Sep; 44(3): 643–53PubMedCrossRefGoogle Scholar
  26. 26.
    Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 1985 Jun; 78 (6 Pt 1): 992–1000PubMedCrossRefGoogle Scholar
  27. 27.
    Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001 Feb 19; 110 (Suppl 3A): 33S–42SPubMedCrossRefGoogle Scholar
  28. 28.
    Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984 Mar 1; 310(9): 563–72PubMedCrossRefGoogle Scholar
  29. 29.
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994 Aug 15; 121(4): 289–300PubMedGoogle Scholar
  30. 30.
    Houston MC. Nonsteroidal anti-inflammatory drugs and anti-hypertensives. Am J Med 1991 May 17; 90(5A): 42S–7SPubMedCrossRefGoogle Scholar
  31. 31.
    Koopmans PP. Pathophysiological and clinical aspects of the interaction between non-steroidal anti-inflammatory drugs (NSAID) and diuretics. Neth J Med 1985; 28(11): 524–9PubMedGoogle Scholar
  32. 32.
    Sturrock ND, Struthers AD. Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function. Br J Clin Pharmacol 1993 Apr; 35(4): 343–8PubMedCrossRefGoogle Scholar
  33. 33.
    Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999 Dec 13; 107(6A): 65S–71SPubMedCrossRefGoogle Scholar
  34. 34.
    Cangiano JL, Figueroa J, Palmer R. Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoar-thritis. Clin Ther 1999 Mar; 21(3): 503–12PubMedCrossRefGoogle Scholar
  35. 35.
    Freed MI, Audet PR, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994 Nov; 34(11): 1098–108PubMedGoogle Scholar
  36. 36.
    Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997 Jun; 24(6): 1137–44PubMedGoogle Scholar
  37. 37.
    Sedor JR, Williams SL, Chremos AN, et al. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clin Pharmacol Ther 1984 Jul; 36(1): 85–91PubMedCrossRefGoogle Scholar
  38. 38.
    Murray MD, Black PK, Kuzmik DD, et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci 1995 Nov; 310(5): 188–97PubMedCrossRefGoogle Scholar
  39. 39.
    Murray MD, Lazaridis EN, Brizendine E, et al. The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci 1997 Aug; 314(2): 80–8PubMedCrossRefGoogle Scholar
  40. 40.
    Aronoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992 Nov; 19 Suppl. 36: 25–31Google Scholar
  41. 41.
    Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles. Fact or fiction? Drug Saf 1994 Mar; 10(3): 183–95PubMedCrossRefGoogle Scholar
  42. 42.
    Ofran Y, Bursztyn M, Ackerman Z. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure. Am J Gastroenterol 2001 Jun; 96(6): 1941PubMedCrossRefGoogle Scholar
  43. 43.
    Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001 Jul; 111(1): 64–7PubMedCrossRefGoogle Scholar
  44. 44.
    Pitkala KH, Strandberg TE, Tilvis RS. Worsening heart failure associated with COX-2 inhibitors. Am J Med 2002 Apr; 112(5): 424–6PubMedCrossRefGoogle Scholar
  45. 45.
    Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002 Jun; 39(6): 1313–7PubMedCrossRefGoogle Scholar
  46. 46.
    Fitzgerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002 Mar 21; 89(6A): 26D–32DPubMedCrossRefGoogle Scholar
  47. 47.
    Harris RC, McKanna JA, Akai Y, et al. Cyxlooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994 Dec; 94(6): 2504–10PubMedCrossRefGoogle Scholar
  48. 48.
    Khan KNM, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol 1998 Sep–Oct; 26(5): 612–20PubMedGoogle Scholar
  49. 49.
    Vio CP, Cespedes C, Gallardo P, et al. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997 Sep; 30 (3 Pt 2): 687–92PubMedCrossRefGoogle Scholar
  50. 50.
    O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993 Sep 13; 330(2): 156–60PubMedCrossRefGoogle Scholar
  51. 51.
    Kömhoff M, Gröne HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997 Apr; 272 (4 Pt 2): F460–8PubMedGoogle Scholar
  52. 52.
    Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997 Jul; 273 (1 Pt 2): F18–26PubMedGoogle Scholar
  53. 53.
    Harris RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002 Mar 21; 89(6A): 10D–7DPubMedCrossRefGoogle Scholar
  54. 54.
    Hao CM, Yull F, Blackwell T, et al. Dehydration activates a NF-kappaB-driven, COX-2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 2000 Oct; 106(8): 973–82PubMedCrossRefGoogle Scholar
  55. 55.
    Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998 Mar; 274 (3 Pt 2): F481–9PubMedGoogle Scholar
  56. 56.
    Yang T, Schnermann JB, Briggs JP. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol 1999 Jul; 277 (1 Pt 2): Fl–9Google Scholar
  57. 57.
    Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999 Apr; 103(7): 953–61PubMedCrossRefGoogle Scholar
  58. 58.
    Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000 May 22; 160(10): 1465–70PubMedCrossRefGoogle Scholar
  59. 59.
    Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999 May; 289(2): 735–41PubMedGoogle Scholar
  60. 60.
    Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000 Jul 4; 133(1): 1–9Google Scholar
  61. 61.
    Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999 Jul; 66(1): 76–84PubMedCrossRefGoogle Scholar
  62. 62.
    Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002 Mar 21; 89(6A): 18D–25DPubMedCrossRefGoogle Scholar
  63. 63.
    Whelton A, Fort JG, Puma JA, et al., SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001 Mar–Apr; 8(2): 85–95PubMedCrossRefGoogle Scholar
  64. 64.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000 Sep 13; 284(10): 1247–55PubMedCrossRefGoogle Scholar
  65. 65.
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22–29; 286(8): 954–9PubMedCrossRefGoogle Scholar
  66. 66.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000 Nov 23; 343(21): 1520–8CrossRefGoogle Scholar
  67. 67.
    White WB, Faich G, Whelton A, et al. Comparison of thrombo-embolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002 Feb 15; 89(4): 425–30PubMedCrossRefGoogle Scholar
  68. 68.
    Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001 Nov 6; 104(19): 2280–8PubMedCrossRefGoogle Scholar
  69. 69.
    Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002 Mar 1; 63(5): 817–21PubMedCrossRefGoogle Scholar
  70. 70.
    Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational study. Lancet 2002 Jan 12; 359(9301): 118–23PubMedCrossRefGoogle Scholar
  71. 71.
    Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Inetrn Med 2002 May 27; 162(10): 1099–104CrossRefGoogle Scholar
  72. 72.
    Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med May 27; 162(10): 1105–10Google Scholar
  73. 73.
    Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002 May 27; 162(10): 1111–5PubMedCrossRefGoogle Scholar
  74. 74.
    Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998 May 25; 158(10): 1108–12PubMedCrossRefGoogle Scholar
  75. 75.
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000 Mar 27; 160(6): 777–84PubMedCrossRefGoogle Scholar
  76. 76.
    Feenstra J. Adverse cardiovascular effects of drugs in patients with heart failure [thesis]. Rotterdam: Erasmus Medical Centre Rotterdam, 2000Google Scholar
  77. 77.
    Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001 Apr; 57(1): 71–5PubMedCrossRefGoogle Scholar
  78. 78.
    Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002 Feb 11; 162(3): 265–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Gysèle S. Bleumink
    • 1
    • 2
  • Johannes Feenstra
    • 3
  • Miriam C. J. M. Sturkenboom
    • 1
  • Bruno H. Ch. Stricker
    • 1
    • 2
  1. 1.Department of Epidemiology & BiostatisticsErasmus Medical CentreRotterdamThe Netherlands
  2. 2.Inspectorate for HealthcareThe HagueThe Netherlands
  3. 3.Department of Internal MedicineAlbert Schweitzer HospitalDordrechtThe Netherlands

Personalised recommendations